Nebivolol Eg

Nebivolol, the active ingredient in Nebivolol Eg, is a beta blocker presented as a tablet for oral use. It lowers blood pressure in adults with primary hypertension and is classified under ATC code C07AB12. GNH USA supplies Nebivolol Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑adrenergic blocker used in the management of cardiovascular conditions, primarily hypertension. - Hypertension: reduces systolic and diastolic blood pressure in patients with primary hypertension. - Heart failure (reduced ejection fraction): may improve cardiac output when incorporated into guideline‑directed therapy. - Chronic stable angina: can decrease myocardial oxygen demand and relieve chest discomfort.

Nebivolol is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially after the first dose. - Fatigue or tiredness. - Nausea or mild gastrointestinal upset. - Bradycardia: heart rate slower than usual. - Peripheral edema: swelling of the lower limbs.

Serious or Rare Side Effects: - Severe bradycardia or heart block requiring medical attention. - Acute bronchospasm in patients with asthma or COPD. - Allergic reactions such as rash, pruritus, or angioedema. - Hepatic dysfunction indicated by elevated liver enzymes. - Cardiogenic shock in patients with advanced heart failure.

Before initiating Nebivolol therapy, clinicians should consider several safety aspects. - Blood pressure monitoring: ensure adequate control and avoid hypotension. - Heart rate assessment: avoid use in patients with resting bradycardia (<50 bpm). - Respiratory caution: use carefully in asthma or chronic obstructive pulmonary disease. - Discontinuation: taper gradually to prevent rebound hypertension. - Concomitant beta‑blockers: avoid additive effects that may cause excessive bradycardia. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol may interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid): - Other beta‑blockers: additive negative chronotropic effects. - Non‑dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem): may cause severe bradycardia. - Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine): increase nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance antihypertensive effect, raising risk of hypotension. - Anti‑arrhythmic agents (e.g., amiodarone): require ECG monitoring. - NSAIDs: can attenuate blood‑pressure‑lowering response. - Insulin or oral hypoglycemics: may mask hypoglycaemia symptoms.